[go: up one dir, main page]

MA46988A1 - Liquid formulation of anti-tnf alpha antibodies - Google Patents

Liquid formulation of anti-tnf alpha antibodies

Info

Publication number
MA46988A1
MA46988A1 MA46988A MA46988A MA46988A1 MA 46988 A1 MA46988 A1 MA 46988A1 MA 46988 A MA46988 A MA 46988A MA 46988 A MA46988 A MA 46988A MA 46988 A1 MA46988 A1 MA 46988A1
Authority
MA
Morocco
Prior art keywords
liquid formulation
tnf alpha
alpha antibodies
antibodies
tnf
Prior art date
Application number
MA46988A
Other languages
French (fr)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA46988A1 publication Critical patent/MA46988A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation liquide d'un anticorps anti-tnf alpha, en particulier l'adalimumab.The present invention relates to a liquid formulation of an anti-tnf alpha antibody, in particular adalimumab.

MA46988A 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibodies MA46988A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
MA46988A1 true MA46988A1 (en) 2020-06-30

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46988A MA46988A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibodies

Country Status (14)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102735988B1 (en) * 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 therapeutic antibody preparations
CN113727730A (en) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 Aqueous formulations of high concentration TNF alpha antibodies
TWI861073B (en) * 2019-03-21 2024-11-11 美商再生元醫藥公司 Stabilized formulations containing anti-il-33 antibodies
EP4108258A4 (en) * 2020-02-20 2024-03-06 Bio-Thera Solutions, Ltd. Anti-tnf-alpha antibody preparation, preparation method therefor and use thereof
AU2021308997A1 (en) * 2020-07-13 2023-02-02 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
AU2022223692A1 (en) * 2021-02-17 2023-09-21 Aptevo Research And Development Llc Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325974B2 (en) * 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP3412310B1 (en) * 2012-03-07 2022-09-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
PE20150964A1 (en) * 2012-09-07 2015-07-25 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB
JP2016505633A (en) 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ TNFα antigen binding protein
HK1215175A1 (en) 2013-03-15 2016-08-19 Bayer Healthcare Llc Anti-prolactin receptor antibody preparation
WO2015134406A1 (en) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
IN2014MU01248A (en) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
EP2946765B1 (en) * 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
EP3250598A1 (en) * 2015-01-28 2017-12-06 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
KR102342292B1 (en) 2021-12-24
JP2022097600A (en) 2022-06-30
NZ757965A (en) 2022-07-01
AU2018236651A1 (en) 2019-10-31
KR20180106974A (en) 2018-10-01
MY197202A (en) 2023-05-31
ZA201906696B (en) 2020-08-26
CO2019010860A2 (en) 2020-01-17
RU2019130728A (en) 2021-04-16
RU2019130728A3 (en) 2021-04-16
BR112019019162A2 (en) 2020-04-14
MX2019010895A (en) 2019-11-05
UA123847C2 (en) 2021-06-09
PH12019502075A1 (en) 2020-09-14
CN110621303A (en) 2019-12-27
JP2020510079A (en) 2020-04-02
AU2018236651B2 (en) 2020-12-10
WO2018169348A1 (en) 2018-09-20
KR20200096472A (en) 2020-08-12
RU2756619C2 (en) 2021-10-04
JP7109849B2 (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MA46988A1 (en) Liquid formulation of anti-tnf alpha antibodies
MA53356B1 (en) Subcutaneous anti-cd38 antibody formulations and uses thereof
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CL2019002250A1 (en) Anti-b7-h3 antibodies and antibody-drug conjugates. (divisional request 201803520)
MA45450B1 (en) Anti-cd19 antibody formulations
MX2019010282A (en) FORMULATION OF MONOCLONAL ANTIBODIES.
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
MX2022001146A (en) Anti-pvrig antibodies formulations and uses thereof.
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
MA40576B1 (en) Anti-her2 antibodies and immunoconjugates
MX2018003410A (en) Humanized anti-human cd19 antibodies and methods of use.
MA38632A1 (en) Anti-transferrin receptor antibody and methods of use
CO6270369A2 (en) NEW SPECIFIC ANTIBODIES OF BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC OR DRUG AGENTS
MX2023014154A (en) ANTI-CCR8 ANTIBODIES.
MA44645B1 (en) Combined treatment of an anti-cd20 antibody with a bcl-2 inhibitor and an mdm2 inhibitor
MA47221A1 (en) Monoclonal antibody to pd-l1
MA38413A1 (en) Pan-elr + cxc chemokine antibody
JOP20200295A1 (en) Mono-specific and multispecific antibodies to the TMEFF2 antagonist and their uses
EA201992027A1 (en) WATER COMPOSITION OF ANTIBODIES AGAINST PD-L1
EP3805390A4 (en) NAV1.7 MONOCLONAL ANTIBODY
MX2022006784A (en) FORMULATIONS OF ANTI-PD-L1 ANTIBODIES.
CL2020002459A1 (en) C-terminal antibody variants
FR3082427B1 (en) COMBINATION OF FACTOR VII AND A BISPECIFIC ANTIBODY ANTI-FACTORS IX AND X
MA45831B1 (en) ANTI-BEDBUG MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
MY199149A (en) Antibody that binds to vegf and il-1beta and methods of use